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HCS Working Group Seminars will take place in 
Thessaloniki, 14-16/2/2013  
 
ACC Meeting is slated for San Francisco, 9-11/3/13 
 
HRS Meeting will take place in Denver, 8-11/5/13  
 
EuroPCR to be held in Paris, 21-24/5/13  
 
EuroPace will be held in Athens, 23-26/6/13  
 
ESC Congress will be held in Amsterdam, 31/8-4/9/13 
 
TCT Meeting: San Francisco, 28/10-1/11/13  
 
AHA 2013: Dallas, 16-20/11/13   
  
Metoprolol is not Effective in Long QT Syndromes 
Types 1 and 2 Compared to Propranolol and Nadolol 
 
The effect of beta blockers was assessed in 382 LQT1/ 
LQT2 patients (56% female, 27% symptomatic, mean 
heart rate 76 bpm, mean QTc 472 ms) started on 
propranolol (n=134), metoprolol (n=147), and nadolol 
(n=101) at a median age of 14 years. The QTc shortening 
with propranolol was significantly greater than with other 
beta-blockers in all patients and in the subset with QTc 
>480 ms. None of the asymptomatic patients had 
arrhythmia events. Among symptomatic patients (n=101), 
15 had syncope. The QTc shortening was significantly 
less pronounced among patients with syncope. There was 
a greater risk of syncope for symptomatic patients 
initiated on metoprolol compared to users of the other 2 
beta-blockers combined, after adjustment for genotype 
(odds ratio: 3.95, p=0.025). Kaplan-Meier analysis 
showed a significantly lower event-free survival for 
symptomatic patients receiving metoprolol compared to 
propranolol/nadolol. The authors concluded that 
propranolol and nadolol are significantly more effective 
than metoprolol in preventing arrhythmic events in 
symptomatic patients. Also, propranolol was superior to 
both nadolol and metoprolol in terms of shortening the 
QTc, particularly in high-risk patients with markedly 
prolonged QTc. Patients with syncope had significantly 
less QTc shortening than the event-free patients 
(Chockalingam P et al, J Am Coll Cardiol 2012;60:2092–
2099).  
 
Still Limitations in Subcutaneous ICD 
 
A total of 118 patients (75% males, mean age 50 
years) received the entirely subcutaneous implantable 
cardioverter defibrillator (S-ICD) system. After 18 
months of follow-up, 8 patients experienced 45 successful 
appropriate shocks (98% first shock conversion efficacy). 
No sudden deaths occurred. Inappropriate shocks 
occurred in 15 patients (13%), mainly due to T-wave 
oversensing, mostly solved by a software upgrade and 
changing the sensing vector of the S-ICD. Complications 
were noted in 16 patients (14%), more frequently in the 
first 15 implantations per center. The authors concluded 
that S-ICD is effective in terminating ventricular 
arrhythmias, but it has still limitations due to its 
subcutaneous position. Inappropriate therapy is an 
important issue in the S-ICD. However, both 
inappropriate shocks and device-related complications 
seemed to be related to a learning curve of both the 
device and the physician (Nordkamp et al, J Am Coll 
Cardiol 2012;60:1933–1939).  
 
Chest Compression Only CPR: More Effective Than 
Conventional CPR 
 
In Japan, over 5 years (2005-2009), among 1376 
bystander-witnessed out-of-hospital cardiac arrests in 
individuals who received CPR and shocks with public-
access automatic external defibrillators (AEDs) by 
bystanders, 506 (36.8%) received chest compression– 
only CPR and 870 (63.2%) received conventional CPR. 
The chest compression–only CPR group (40.7%, 206 of 
506) had a significantly higher rate of 1-month survival 
with favorable neurological outcome than the 
conventional group (32.9%, 286 of 870; adjusted odds 
ratio, 1.33). The authors concluded that compression-only 
CPR is more effective than conventional CPR for patients 
in whom out-of-hospital cardiac arrest is witnessed and 
shocked with public-access defibrillation (Iwami T et al, 
Circulation 2012;126:2844-2851) 
 
Hypothermia in Out-of-Hospital Cardiac Arrest: 
Better Outcome with Lower Cooling Level (32o C) 
 
Patients (n=36; 26 shockable rhythm, 10 asystole) 
with a witnessed out-of-hospital cardiac arrest were 
cooled to a target temperature of either 32°C (n=18) or 
34°C (n=18) for 24 hours followed by 12-24 hours of 
controlled rewarming. Survival free from severe 
dependence was accomplished in 8/18 patients in the 
32°C group (44.4%) compared with 2 of 18 in the 34°C 
group (11.1%) (P=0.12). All patients whose initial 
rhythm was asystole died before 6 months in both groups. 
Of those with initial shockable rhythm assigned to 32°C, 
8/13 (61.5%) were alive free from severe dependence at 6 
months compared with 2 of 13 (15.4%) assigned to 34°C 
(log-rank P=0.029). Complication rate was similar in 
both groups except for the incidence of seizures, which 
was lower (1 vs 11; P=0.0002) in patients assigned to 
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32°C compared with 34°C; but there was a trend toward a 
higher incidence of bradycardia (7 versus 2; P=0.054) in 
patients assigned to 32°C. Although potassium levels 
decreased to a greater extent in patients assigned to 32°C, 
the incidence of hypokalemia was similar in both groups. 
The authors concluded that a lower cooling level may be 
associated with a better outcome in patients surviving 
out-of-hospital cardiac arrest secondary to a shockable 
rhythm (Lopez-de-Sa E et al, Circulation 2012;126: 
2826-2833) 
 
Atrial Fibrillation: Rhythm Control is Superior, With 
Lower Rates of Stroke 
 
In Quebec during the period 1999 to 2007, among 
16325 patients >65 years with atrial fibrillation (AF) who 
filled a prescription for thyrhm control and 41193 patients 
who had rate control therapy, at a mean follow-up of 2.8 
years (max 8.2 years), fewer patients on rhythm control 
therapy than on rate control therapy had a CHADS2 score 
of >2 (58.1% vs 67.0%, P<0.001). Treatment with 
antithrombotics was comparable in the 2 groups (76.8% 
vs 77.8%). Incidence of stroke/TIA was lower in patients 
treated with rhythm control (1.74 vs 2.49, per 100 person-
years, P<0.001). This association was more pronounced 
in the moderate- and high-risk groups. In multivariable 
analysis, rhythm control therapy was associated with a 
lower risk of stroke/TIA (hazard ratio, 0.80). Lower 
stroke/TIA rate was confirmed in a propensity score–
matched cohort. The authors concluded that compared 
with rate control therapy, rhythm control was associated 
with lower rates of stroke/TIA among patients with AF, 
more so in those with moderate and high risk of stroke 
(Tsadok MA et al, Circulation 2012;126:2680-2687) 
 
Novel Oral Anticoagulants: a Metaanalysis Finds 
Them More Efficacious  
 
A meta-analysis of 12 phase II an III randomized, 
controlled trials comparing novel oral anticoagulants 
(NOACs) (3 with dabigatran, 4 with rivaroxaban, 2 with 
apixaban, and 3 with edoxaban) with vitamin K 
antagonists in 54875 patients with atrial fibrillation 
indicated that NOACs significantly reduced total 
mortality (5.61% vs 6.02%; RR, 0.89), cardiovascular 
mortality (3.45% vs 3.65%; RR, 0.89), and stroke/ 
systemic embolism (2.40% vs 3.13%; RR, 0.77). There 
was a trend toward reduced major bleeding (RR, 0.86) 
with a significant reduction of intracranial hemorrhage 
(RR, 0.46). No difference in myocardial infarction was 
observed. The authors concluded that NOACs are 
associated with an overall clinical benefit compared with 
vitamin K antagonists (Dentali F et al, Circulation 
2012;126:2381-2391) 
 
Colchicine Reduces Early AF Recurrences After 
Ablation 
 
Patients with paroxysmal atrial fibrillation (AF) 
undergoing radiofrequency ablation were randomized to a 
3-month course of colchicine 0.5 mg twice daily or 
placebo. Over 3 months, AF recurred in 27 (33.5%) of 80 
patients receiving placebo and in 13 (16%) of 81 patients 
receiving colchicine (odds ratio: 0.38). Diarrhea was 
reported in 7 patients in the colchicine group (8.6%) and 
1 in the placebo group (1.3%, p = 0.03). Higher 
reductions in CRP and interleukin (IL)-6 levels were 
observed in the colchicine group. The authors concluded 
that colchicine is an effective and safe treatment for 
prevention of early AF recurrences after pulmonary vein 
isolation and is associated with a significant decrease in 
inflammatory mediators (Deftereos S et al, J Am Coll 
Cardiol 2012;60: 1790–1796)  
 
ARISTOTLE Trial: Apixaban Reduces Stroke, Death, 
and Major Bleeding Regardless of Renal Function 
 
Among patients with atrial fibrillation (AF) in the 
ARISTOTLE trial treated with apixaban, a novel oral 
anticoagulant with partial renal excretion, there were 
7518 patients (42%) with an estimated GFR (eGFR) of 
>80 mL/min, 7587 (42%) between >50 and 80 mL/min, 
and 3017 (15%) with an eGFR of ≤50 mL/min. 
Cardiovascular and bleeding events were more in patients 
with impaired renal function (≤80 mL/min). Apixaban 
was more effective than warfarin in preventing stroke or 
systemic embolism and reducing mortality irrespective of 
renal function. These results were consistent, regardless 
of methods for GFR estimation. Apixaban was associated 
with less major bleeding events across all ranges of 
eGFRs. The authors concluded that in patients with AF, 
renal impairment was associated with increased risk of 
cardiovascular events and bleeding. When compared with 
warfarin, apixaban reduced stroke, death, and major 
bleeding, regardless of renal function. Patients with 
impaired renal function seemed to have the greatest 
reduction in major bleeding with apixaban (Hohnloser SH 
et al, Eur Heart J 2012; 33: 2821–2830)  
 
MASTER Trial: Superior Rates of Epicardial 
Coronary Flow and Complete ST Segment Resolution 
with the MGuard Micronet Mesh–Covered Stent 
Compared with Conventional Metal Stents  
 
A total of 433 patients with STEMI presenting within 
12 h and undergoing PCI were randomized to the 
MGuard (a novel thin-strut metal stent with a 
polyethylene terephthalate micronet) (n=217) or 
commercially available bare metal or drug-eluting stents 
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(n=216). The primary endpoint of post-procedure 
complete ST-segment resolution was significantly 
improved in patients randomized to the MGuard stent 
compared with control patients (57.8% vs 44.7%; p = 
0.008). The MGuard stent compared with control stents 
also resulted in superior rates of TIMI 3 flow (91.7% vs. 
82.9%, p = 0.006) with comparable rates of myocardial 
blush grade 2 or 3 (83.9% vs. 84.7%, p = 0.81). Mortality 
(0% vs. 1.9%, p = 0.06) and major adverse cardiac events 
(1.8% vs. 2.3%, p=NS) at 30 days were not significantly 
different between patients randomized to the MGuard 
stent and control stent. The authors concluded that among 
patients with STEMI undergoing emergent PCI, the 
MGuard micronet mesh–covered stent compared with 
conventional metal stents resulted in superior rates of 
epicardial coronary flow and complete STsegment 
resolution (Stone GW et al, J Am Coll Cardiol 
2012;60:1975–1984).   
 
SIMPLICITY HTN-2: Benefit of Renal Denervation 
Persists at 1 Year  
 
Catheter-based renal denervation produced significant 
blood pressure lowering in resistant hypertension (HTN) 
at 1 year (n=47) with a mean fall in office systolic blood 
pressure of -28.1 mm Hg (P<0.001) similar to the 6-
month fall (-31.7 mm Hg; P=0.16). The mean systolic 
blood pressure of the crossover group 6 months after the 
procedure was also significantly lowered (from 
190.0+19.6 to 166.3+24.7 mm Hg; change, -23.7+27.5; 
P<0.001). Complications: 1 renal artery dissection 
corrected by stenting, and 1 hypotensive episode. The 
authors concluded that the effect of renal denervation is 
sustained at 1 year and that patients who crossed over to 
renal denervation with the Symplicity system had a 
significant drop in blood pressure similar to that observed 
in patients receiving immediate denervation (Esler MD et 
al, Circulation 2012;126:2976-2982.)  
 
Novel Hypocholesterolemic Drug Appears Promising 
in Phase 1 Studies 
 
AMG 145 is a human monoclonal antibody to 
proprotein convertase subtilisin/kexin type 9 (PCSK9: a 
down-regulator of surface expression of the LDL receptor 
that leads to increased LDL cholesterol). AMG 145 
prevents PCSK9/LDL receptor interaction, restoring 
LDL-receptor recycling. The drug was administered 
subcutaneously either once weekly (QW) or every 2 
weeks (Q2W) or every 4 weeks in healthy (phase 1a) and 
hypercholesterolemic adults (phase 1b) receiving statins. 
In the trials (AMG 145 n = 85, placebo n = 28), AMG 
145 reduced LDL cholesterol up to 64% (p < 0.0001) vs 
placebo after 1 dose >21 mg and up to 81% (p < 0.001) 
with repeated doses >35 mg QW. No serious adverse 
events occurred. The authors concluded that in phase 1 
studies, AMG 145 significantly reduced serum LDL 
cholesterol in healthy and hypercholesterolemic statin-
treated subjects, with an overall side-effect profile similar 
to placebo (Dias CS et al, J Am Coll Cardiol 2012;60: 
1888–1898).  
 
Ablation Results are Poor in Long-Standing Persistent 
AF, Unless Arrhythmia Duration is < 2 Years  
 
A single ablation procedure was successful in 
maintaining sinus rhythm (SR) for a mean duration of 56 
months only in 41 of 202 (20.3%) patients with long-
standing atrial fibrillation (AF). Multiple procedures 
increased the success rate to 45% (91 of 202 patients 
including 24 patients receiving antiarrhythmic drugs). In 
105 patients, pulmonary vein isolation (PVI) was the sole 
ablative therapy, 49 (46.7%) of those patients remained in 
SR during follow-up. Patients with a total AF duration of 
<2 years had a higher ablation success rate than the other 
patients with longer AF duration (76.5% vs. 42.2%; p = 
0.033). The authors concluded that over 5 years, single 
ablation procedure had a poor (20%) success rate in 
patients with long-standing AF; multiple ablation 
procedures increased success to 45%. For patients with a 
total AF duration of <2 years, the outcomes were more 
favorable (Tilz RR et al, J Am Coll Cardiol 2012;60: 
1921–1929).  
 
PRAGUE 12 Study: No Improved Clinical Outcomes 
at 1 Year after Surgical Ablation of Atrial Fibrillation 
 
A total of 224 patients with AF scheduled for valve 
and/or coronary surgery were randomized into 2 groups: 
group A (left atrial surgical ablation, n = 117) vs. group B 
(no ablation, n = 107). Sinus rhythm (SR) was found at 
Holter-ECG after 1 year in 60.2% of group A patients vs. 
35.5% in group B (P = 0.002). The combined safety end-
point (death/myocardial infarction/stroke/renal failure) at 
30 days occurred in 10.3% (group A) vs. 14.7% (group B, 
P = 0.411). All-cause 1-year mortality was 16.2% (A) vs. 
17.4% (B, P = 0.8). Stroke occurred in 2.7% (A) vs. 4.3% 
(B) patients (P = 0.319). No difference (A vs. B) in SR 
was found among patients with paroxysmal (61.9 vs. 
58.3%) or persistent (72 vs. 50%) AF, except in patients 
with longstanding persistent AF (53.2 vs. 13.9%, P < 
0.001). The authors concluded that surgical ablation 
improves SR presence post-operatively without 
increasing peri-operative complications. However, this 
did not translate into improved clinical outcomes at 1 





Balloon Dilation and Atrial Fibrillation Account for 
Stroke in TAVI Patients  
 
Among 1061 patients undergoing transcatheter aortic 
valve implantation (TAVI) with a balloon-expandable 
(64%) or self-expandable (36%) valve, cerebrovascular 
events (CVEs) occurred in 54 patients (5.1%) within 30 
days (54% acute). The predictors of acute CVEs were 
balloon postdilation of the valve prosthesis (odds ratio-
OR, 2.46) and valve dislodgment/embolization (OR, 
4.36); new-onset atrial fibrillation (AF) (OR, 2.76) was a 
predictor of subacute CVEs. Late (median 12 months) 
CVEs (35 patients- 3.3%) were predicted by chronic AF 
(hazard ratio-HR, 2.84), peripheral vascular disease (HR, 
2.02), and prior CVEs (HR, 2.04). The authors concluded 
that in a large cohort of patients undergoing TAVI, acute 
CVEs were predicted by balloon postdilation and valve 
dislodgment/embolization, while new-onset AF conferred 
a higher risk for subacute events. Late events were 
predicted by history of chronic AF and peripheral and 
cerebrovascular disease (Nombela-Franco L et al, 
Circulation 2012;126: 3041-3053). 
 
Thromboaspiration During Primary PCI Reduces 
Mortality 
 
Thrombus aspiration was performed in 1095 patients 
of 2567 patients (42.7%) with ST-elevatiom myocardial 
infarction (STEMI) treated with primary percutaneous 
coronary intervention (PCI). Post-PCI TIMI 3 flow was 
more frequently achieved in the thromboaspiration group 
(odds ratio-OR, 1.92; P = 0.0004). Overall in-hospital and 
10-month mortality rates were 4.5 and 9.0%, respectively. 
Thromboaspiration was associated with a significant 
reduction in in-hospital (adjusted OR: 0.51, P = 0.027) 
and longer term mortality (hazard ratio-HR: 0.69, P = 
0.028). Reduced longer term mortality was only 
significant in those with a total ischemic time ≤180 min 
(P = 0.001). The authors concluded that thrombus 
aspiration during primary PCI is associated with a 
significant reduction in mortality, especially in those with 
a short total ischemic time (Noman A et al, Eur Heart J 
2012; 33, 3054–3061) 
 
Danish Study: Discontinuation of Clopidogrel 1 Year 
after MI is Associated with an Increased Risk of 
Death or Recurrent MI  
 
Of 29 268 patients treated with clopidogrel after a first 
myocardial infarction (MI) (2004-2009) and included in a 
Danish retrospective nationwide study, who discontinued 
clopidogrel after 1 year, 3214 (11.0%) experienced death 
or recurrent MI at a follow-up of 18 months. There were 
9819 (33.6%) patients treated only medically and 19 449 
(66.4%) patients treated with PCI. At 12 months after the 
index MI, for patients treated only medically, the risk of 
death or recurrent MI in the first 90-day period of 
clopidogrel discontinuation was 1.07 (P= 0.79) (adjusted 
incidence rate ratio-IRR). For patients treated with PCI, 
the corresponding IRR was 1.59 (P= 0.013). The risk of 
recurrent MI yielded an IRR of 0.77 (P= 0.51) for 
patients treated only medically and 1.87 (P= 0.019) for 
PCI-treated patients. The authors concluded that 
discontinuation of clopidogrel 12 months after MI is 
associated with an increased risk of death or recurrent MI 
in the first 90 days of discontinuation compared with the 
next 90-day period of discontinuation for patients treated 
with PCI, but not for patients not treated with PCI 
(Charlot M et al, Eur Heart J 2012; 33:2527-2534)  
 
Important Review and Other Articles  
 
Catheter-assisted pulmonary embolectomy 
(Sobieszczyk P, Circulation 2012;126: 1917-1922), 2012 
ACCF/AHA/HRS Focused Update of the 2008 guidelines 
for device-based therapy of cardiac rhythm abnormalities 
(Tracy CM et al, J Am Coll Cardiol 2012;60:1297-1313), 
Third universal definition of myocardial infarction 
(Thygesen K et al, J Am Coll Cardiol 2012; 60:1581-
1598), Percutaneous treatment of PFO and ASDs (Tobis 
& Shenoda, J Am Coll Cardiol 2012; 60:1722-1732), 
Nonsustained ventricular tachycardia (Katritsis D et al, J 
Am Coll Cardiol 2012; 60: 1993-2004), Quantitation of 
mitral regurgitation (Grayburn PA et al, Circulation 
2012; 126:2005-2017), 2012 ESC/EACTS Guidelines on 
the management of valvular heart disease (Eur Heart J 
2012; 33: 2451-2496), 2012 ESC Guidelines for the 
management of STEMI (Eur Heart J 2012; 33: 2569-
2619), 2012 ESC Guidelines for the management of atrial 
fibrillation (Eur Heart J 2012; 33: 2719-2747), Low-
flow low-gradient aortic stenosis (Pibarot & Dumesnil, J 
Am Coll Cardiol 2012; 60:1845-1853), Update on 
pulmonary embolism (Konstantinides & Goldhaber, Eur 
Heart J 2012; 33: 3014-3022), 2012 ACCF/AHA/ 
ACP/AATS/PCNA/ SCAI/STS Guideline for the 
diagnosis and management of patients with stable 
ischemic heart disease (Fihn SD et al, Circulation 
2012;126:3097-3137; J Am Coll Cardiol 2012;60: 2564-
2603), AHA Recommendations for the use of mechanical 
circulatory support (Peura JL et al, Circulation 
2012;126:2648-2667), ACCF 2012 Expert Consensus 
Document on Practical Clinical Considerations in the 
Interpretation of Troponin Elevations (Newby LK et al, J 
Am Coll Cardiol 2012;60:2427-2463), Inflammation in 
atrial fibrillation (Guo Y et al, J Am Coll Cardiol 
2012;60:2263-2270), Optical coherence tomography 
(OCT) (Prati F et al, Eur Heart J 2012; 33:2513-2520) 
